TTOO - T2 Biosystems, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.56
-0.07 (-1.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.63
Open6.61
Bid6.35 x 1000
Ask7.48 x 800
Day's Range6.38 - 6.67
52 Week Range3.60 - 9.98
Volume445,648
Avg. Volume961,725
Market Cap287.115M
Beta1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.75
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of TTOO earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 T2 Biosystems Inc Earnings Call

  • GlobeNewswire10 days ago

    T2 Biosystems Reports Granting of Inducement Awards

    T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.

  • Associated Press14 days ago

    T2 Biosystems: 2Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 32 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire14 days ago

    T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Quarterly Product Revenue Up 71% Year-Over-Year. Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio. Reiterates 2018 Financial Guidance, Including ...

  • GlobeNewswire23 days ago

    T2 Biosystems to Participate in Two Upcoming Conferences

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. This conference will allow institutional investors to meet with the Company but does not include a formal presentation. The second conference is the Canaccord Genuity 38th Annual Growth Conference, which is being held August 8-9 in Boston.

  • GlobeNewswire27 days ago

    T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date

    LEXINGTON, Mass., July 20, 2018-- T2 Biosystems, Inc., an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today ...

  • GlobeNewswirelast month

    T2 Biosystems Reports Granting of Inducement Awards

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on July 2, 2018 it issued inducement awards to three new employees. The inducement awards consist of options to purchase 19,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $7.82, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on July 2, 2018.

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Thermo Fisher Scientific and Three Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / June 29, 2018/ If you want a free Stock Review on TMO sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following Medical Laboratories and Research stocks for observation: Syneos Health Inc. (NASDAQ: SYNH), T2 Biosystems Inc. (NASDAQ: TTOO), Thermo Fisher Scientific Inc. (NYSE: TMO), and Bruker Corp. (NASDAQ: BRKR).

  • GlobeNewswire2 months ago

    T2 Biosystems Added to the Russell 3000® Index

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it has been added to the broad-market Russell 3000® Index. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • GlobeNewswire2 months ago

    Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today late-breaker posters and data presented at the American Society for Microbiology (ASM) Microbe conference on June 7-11 that demonstrate the T2Bacteria® Panel’s accuracy and speed, which may enable more rapid treatment of patients with bloodstream infections in order to prevent sepsis. “The strong customer data and conclusions expressed by clinicians at ASM Microbe on T2Bacteria are encouraging and allows us to further strengthen the momentum generated by FDA clearance two weeks ago,” said John McDonough, president and chief executive officer, T2 Biosystems. “We are already seeing excitement in the market, as healthcare providers recognize the potential of the T2Bacteria Panel to prevent the progression of bloodstream infections to sepsis.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TTOO earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 T2 Biosystems Inc Earnings Call

  • PR Newswire2 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • GlobeNewswire2 months ago

    T2 Biosystems Reports Granting of Inducement Awards

    The inducement awards consist of options to purchase 15,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $8.85, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on June 4, 2018. T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before.

  • GlobeNewswire2 months ago

    T2 Biosystems Announces Closing of Public Offering of Common Stock

    T2 Biosystems, Inc. (TTOO) today announced the closing of its underwritten public offering of 7,015,000 shares of common stock, including 915,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.50 per share, before underwriting discounts, for gross proceeds of approximately $52.6 million. All of the shares of common stock sold in the offering were offered by T2 Biosystems. Leerink Partners LLC acted as the book-running manager for the offering.  Canaccord Genuity LLC acted as passive book-running manager.

  • TheStreet.com2 months ago

    How to Manage Risk in Biotech Stocks

    Karl is an ex-Brooklynite who now splits time between Miami and London. The ascendancy of the Evil Empire (AKA, my beloved NY Yankees) and the fate of his miserable Mets, who look more like a M.A.S.H. unit than a baseball team for the third year in a row. Karl was quite happy with the news as he had taken my advice and loaded up on the shares in the mid-$4s several months ago and now the stock was trading near $10 on the news.

  • Here's Why T2 Biosystems, Inc. Rose Over 16% Today
    Motley Fool2 months ago

    Here's Why T2 Biosystems, Inc. Rose Over 16% Today

    The diagnostic company is rebounding after a stock offering.

  • GlobeNewswire2 months ago

    T2 Biosystems to Present at the Jefferies 2018 Global Healthcare Conference

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the Jefferies 2018 Global Healthcare Conference. The presentation will be webcast live and available for replay and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.

  • GlobeNewswire3 months ago

    T2 Biosystems Announces Pricing of Public Offering of Common Stock

    T2 Biosystems, Inc. (TTOO) today announced the pricing of an underwritten registered public offering of 6,100,000 shares of common stock at a public offering price of $7.50 per share, before underwriting discounts, for gross proceeds of $45,750,000. T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock at the public offering price, less the underwriting discount.  All of the shares of common stock to be sold in the offering will be issued by T2 Biosystems. Leerink Partners LLC is acting as the book-running manager for the offering.  Canaccord Genuity LLC is acting as passive book-running manager.  Janney Montgomery Scott LLC, JonesTrading Institutional Services LLC and WBB Securities LLC are acting as co-managers for the offering.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on May 29) Ascendis Pharma A/S (NASDAQ: ASN ) ASLAN PHARMACEUTICALS ...

  • GlobeNewswire3 months ago

    T2 Biosystems Announces Proposed Public Offering of Common Stock

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, today announced that it is commencing an underwritten registered public offering of 5,650,000 shares of its common stock. T2 Biosystems also intends to grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.  All of the shares are being offered by T2 Biosystems. Leerink Partners LLC is acting as joint book-running manager for the offering.  Canaccord Genuity LLC is acting as passive book-running manager.  Janney Montgomery Scott LLC, JonesTrading Services LLC and WBB Securities, LLC are acting as co-managers for the offering.

  • Benzinga3 months ago

    T2Biosystems Announces FDA Approval For Sepsis Test: 'This Is A Game-Changer'

    T2 Biosystems Inc (NASDAQ: TTOO ) announced Tuesday  that it received FDA approval for a blood test to detect sepsis; the stock is down more than 11 percent in morning trading.  What Happened T2 Biosystems announced ...

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Momo Inc (ADR) (NASDAQ: MOMO ) was trading higher ...

  • GlobeNewswire3 months ago

    T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, today announced that it has received market clearance from the U.S. Food and Drug Administration (FDA) for the T2Bacteria® Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. The T2Bacteria Panel, for the first time, provides sensitive detection of specific sepsis-causing bacterial pathogens directly from a whole blood specimen in approximately 5 hours. All other FDA-cleared diagnostic tests that detect bacteria in blood require a positive blood culture sample prior to bacterial species specific identification, which typically delays results by one to five days.

  • Associated Press3 months ago

    T2 Biosystems: 1Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...